This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.

Slides:



Advertisements
Similar presentations
Neurological Diseases Jerry Carley RN, MSN, MA, CNE
Advertisements

FACULTY OF MEDICINE PHYSIOLOGY DEPARTMENT DR. NERMEN MADY DR. RAMEZ.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 15 Cholinesterase Inhibitors and Their Use in Myasthenia Gravis.
Myasthenia Gravis Dr. Belal M. Hijji, RN. PhD February 29, 2012.
Muscle weakness Index case Year 1 Michaelmas Term.
Guillain-Barré Syndrome, Myasthenia Gravis,
Terri Kueber, CRNA, MS. Explain the pathophysiology and classification of Myasthenia Gravis (MG) List the signs and symptoms and clinical manifestation.
37 yo F Engineer PC: Double vision, fatigue, difficulty swallowing. HPC: - 3/52 of worsening diplopia, worse in afternoons - 3/7 of intermittent weakness.
NEUROMUSCULAR JUNCTION DR. ZAHOOR ALI SHAIKH LECTURE
Agents Used to Treat Musculoskeletal Health Alterations.
Therapeutic Plasma Exchange for Myasthenia Gravis Clifford Blieden, MD Houston Methodist Hospital Department of Pathology and Genomic Medicine, Division.
 Myasthenia gravis is a chronic autoimmune neuromuscular disease that is characterized by different degrees of weakness of the skeletal muscles of the.
1 Review of Musculoskeletal System Chapter Muscle Skeletal muscle > 600 muscles in body Fascia –Epimysium – forms tendons at ends –Perimysium –
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Myasthenia Gravis Blaine Suing November 21 st 2007.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
GENERAL THORACIC SURGERY CHAPTER 168
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
Public Health – Dresden Medical School Complementary care seeking behavior in patients with Myasthenia gravis J. Klewer 1, L. Wondzinski 1, A. Friedrich.
Myasthenia Gravis 重症肌无力(MG)
Myasthenia Gravis.  Describe myasthenia gravis  Signs and Symptoms of the disease  Describe the treatments available Purpose and Objectives.
MYASTHENIA GRAVIS (MG)
Sophia M. Chung, M.D. Depts of Ophthalmology &
An autoimmune neurologic disorder
Myasthenia Gravis Victor Politi,M.D.
MYASTHENIA GRAVIS ANESTHESIOLOGY Jasdeep Dhaliwal Clinical Rotation.
Pathophysiology, Diagnosis and Medical Management of Myasthenia Gravis
Linda S. Williams / Paula D. Hopper Copyright © F.A. Davis Company Understanding Medical Surgical Nursing, 4th Edition Chapter 50 Nursing Care of.
Medical and Surgical Management of MG Brian A. Crum, MD Department of Neurology Mayo Clinic Rochester, MN MGFA National Meeting, St. Louis May, 2010.
This lecture was conducted during the Nephrology Unit Grand Ground by Registrar under Nephrology Division under the supervision and administration of Prof.
+ This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Myasthenia Gravis.
Disorders of the Neuromuscular Junction
Myasthenia Gravis.
Neurology Chapter of IAP
Myasthenia Gravis: An inheritable disorder or an acquired auto-immune response Research in Allied Health Jeri Frazier November 1, 2005.
NEUROPATHY Subsection B3 Francisco – Go, Kerby + Laxamana September 16, 2009.
MYASTHENIA GRAVIS Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital.
MYASTHENIA GRAVIS “FROM WEAKNESS SHALL COME STRENGTH”. BY PATTI HAMILTON.
Myasthenia Gravis Anastasiya Lukecha Psychology 4th.
Emmett West Hour Myasthenia Gravis Muscular System.
Kaitlyn Bradshaw. Is a rapid pain under any voluntary muscle DESCRIPTION.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Assessment and Treatments  History: weakness caused by any precipitating factors ( i.e. infection, emotional upset)  Time of weakness: after repeated.
Copyright © 2006 by Mosby, Inc. Slide 1 Chapter 30 Myasthenia Gravis Figure Myasthenia gravis. Inset, Atelectasis, a common secondary anatomic alteration.
Autonomic Nervous System (ANS) Cholinergic Drugs 4 أ0م0د.وحدة بشير اليوزبكي.
Nursing management of Myasthenia Gravis
Myasthenia Gravis.
Nursing Care of Patients with Peripheral Nervous System Disorders.
Understanding Medical Surgical Nursing, 4th Edition CHAPTER 50 Nursing Care of Patients with Peripheral Nervous System Disorders.
This lecture was conducted during the Nephrology Unit Grand Ground by Registrar under Nephrology Division under the supervision and administration of Prof.
Jennifer Vilarino Period: 5
Neuromuscular disorders
Myasthenia Gravis.
Neuromuscular junction
Muscular Disorders and Diseases
Manage a Neurological Mystery
Myasthenia Gravis Johan Perrand Period 3.
Myasthenia Gravis.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Myasthenia gravis By: Nikki Young.
“Grave Muscle Weakness”
Figure 1 Neuromuscular junction in myasthenia gravis (MG)
Presentation transcript:

This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration of Prof. Jamal Al Wakeel, Head of Nephrology Unit, Department of Medicine and Dr. Abdulkareem Al Suwaida, Chairman of the Department of Medicine. Nephrology Division is not responsible for the content of the presentation for it is intended for learning and /or education purpose only.

MYASTHENIA GRAVIS Presented by: Fayez Al Rogi Medical Student February 2009

DEFINITION Chronic autoimmune neuromuscular disease. It is a disorder of neuromuscular function thought to be due to the presence of antibodies to acetylcholine receptors at the neuromuscular junction.

PREVALENCE Prevalence of 50,000 cases in US. All ethnic groups and both genders. Female to male ratio – 20 to 40 years (females 1.5:1) – 50 to 70 years (males 1.5:1)

IMMUNOPATHOLOGY Autoantibody (antagonistic) for acetylcholine receptor at post-synaptic neuromuscular junction. The nerve cell conveys its message to tell the muscle to contract. The antibodies interfere with the message and the muscle contracts less efficiently. Resulting in the weakness of the arms or legs or of the muscles of the head.

Acetylcholine receptors are – Blocked – Altered – Destroyed

75% of patients have thymus abnormality: – 85% thymic hyperplasia – 15% thyroma – Disease usually more severe with thymus abnormality.

ETIOLOGY The cause is unkown.

CLINICAL FEATURES Drooping of the eyelids ( Drooping of the eyelids (Ptosis). Double vision. Double vision. Facial muscles weakness. Difficulty in swallowing (dysphagia). Difficulty in swallowing (dysphagia). Weakness of arms, hands, fingers, legs. Difficulty breathing if chest muscle are affected. Difficulty breathing if chest muscle are affected.

DiplopiaPtosis

Exacerbation of MG Emotional stress Pregnancy Menses Secondary illness Trauma Temperature extremes Hypokalemia Drugs – aminoglycosides antibiotics, beta blockers, procainamide, quinidine, phentoin, and some psychotropic drugs

DIAGNOSIS OF MG History. Physical examinations for muscle fatigue. Edrophonium Test. EMG. Lab Dx. CT of thymus gland.

 Edrophonium Test (Tensilon) – IV administration of Edrophonium chloride – Blocks degradation of acetylcholine – Brief relief of eye weakness

Laboratory Dx  Acetylcholine receptor antibody (Anti-AChR) Acetylcholine receptor antibody, binding – 90% generalized – 70% ocular Acetylcholine receptor antibody, blocking – 50% generalized – 20% ocular Acetylcholine receptor antibody, modulating – 90% generalized – 70% ocular

 Muscle-specific tyrosine kinase antibody – Anti-MuSK – 45% of seronegative MG

TREATMENT Anticholinesterase agents – Neostigmine (Prostigmin) – Pyridostigmine (Mestinon) Corticosteroids / Immunosuppressive agents – Prednisone – Azathioprine Intravenous Immunoglobulin (IVIG) Thymectomy Plasmapheresis (plasma exchange)

LIFESTYLES A person with Myasthenia Gravis can lead a normal life if the medications are taken in the correct dosages and at the right time of the day.

THANK YOU